Kiora Pharmaceuticals Inc (KPRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kiora Pharmaceuticals Inc (KPRX) has a cash flow conversion efficiency ratio of -0.057x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.27 Million) by net assets ($22.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kiora Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Kiora Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Kiora Pharmaceuticals Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Kiora Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kiora Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Iron Road Ltd
AU:IRD
|
-0.021x |
|
Allergy Therapeutics
LSE:AGY
|
0.748x |
|
TME Pharma N.V.
PA:ALTME
|
5.018x |
|
BPH Energy Ltd
AU:BPH
|
-0.008x |
|
Martina Berto Tbk
JK:MBTO
|
0.057x |
|
Finansa Public Company Limited
BK:FNS
|
-0.224x |
|
Equity Story Group Ltd
AU:EQS
|
0.833x |
|
PPHE Hotel Group Ltd
LSE:PPH
|
0.062x |
Annual Cash Flow Conversion Efficiency for Kiora Pharmaceuticals Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Kiora Pharmaceuticals Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Kiora Pharmaceuticals Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $25.76 Million | $8.56 Million | 0.332x | +121.24% |
| 2023-12-31 | $6.11 Million | $-9.56 Million | -1.564x | -71.12% |
| 2022-12-31 | $11.41 Million | $-10.43 Million | -0.914x | -24.84% |
| 2021-12-31 | $14.58 Million | $-10.68 Million | -0.732x | +2.63% |
| 2020-12-31 | $9.73 Million | $-7.32 Million | -0.752x | +38.92% |
| 2019-12-31 | $6.62 Million | $-8.15 Million | -1.231x | -1.46% |
| 2018-12-31 | $8.94 Million | $-10.84 Million | -1.214x | -136.15% |
| 2017-12-31 | $-1.93 Million | $-6.47 Million | 3.357x | -86.86% |
| 2016-12-31 | $-329.42K | $-8.41 Million | 25.539x | +3586.11% |
| 2015-12-31 | $6.09 Million | $-4.46 Million | -0.733x | -3184.65% |
| 2014-12-31 | $-40.03 Million | $-950.62K | 0.024x | -69.25% |
| 2013-12-31 | $-38.29 Million | $-2.96 Million | 0.077x | -48.50% |
| 2012-12-31 | $-34.81 Million | $-5.22 Million | 0.150x | -- |
About Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also deve… Read more